Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study.

Mills, Anthony

Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study. [electronic resource] - Journal of acquired immune deficiency syndromes (1999) Feb 2013 - 164-70 p. digital

Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

1944-7884

10.1097/QAI.0b013e31827b51b5 doi


Adenine--analogs & derivatives
Adolescent
Adult
Aged
Anti-HIV Agents--therapeutic use
Atazanavir Sulfate
CCR5 Receptor Antagonists
CD4 Lymphocyte Count
Cyclohexanes--adverse effects
Deoxycytidine--analogs & derivatives
Drug Therapy, Combination--adverse effects
Emtricitabine
Female
HIV Fusion Inhibitors--adverse effects
HIV Infections--drug therapy
HIV-1
Humans
Male
Maraviroc
Middle Aged
Oligopeptides--therapeutic use
Organophosphonates--therapeutic use
Pilot Projects
Pyridines--therapeutic use
RNA, Viral--blood
Ritonavir--therapeutic use
Tenofovir
Triazoles--adverse effects
Viral Load
Young Adult